Blockade of IL-8 with a neutralizing antibody can ameliorate arthritis and reduce the infiltration of neutrophils into the joints during the early phase of inflammation, further demonstrating that IL-8 acts as a neutrophil chemotactic factor [18]. Here, CXCL8 is linked to arthritic joint disease.